EndoChoice (GI) Misses Q2 EPS by 16c

EndoChoice (NYSE: GI) reported Q2 EPS of ($1.01), $0.16 worse than the analyst estimate of ($0.85). Revenue for the quarter came in at $18.6 million versus the consensus estimate of $17.59 million.

On a non-GAAP basis, the Company reported Adjusted EBITDA of ($9.6) million, or (51%) of revenue, for the second quarter 2015, compared to ($10.5) million, or (69%) of revenue, for the second quarter 2014.

EndoChoice sees FY2015 EPS of ($2.85)-($2.70), versus the consensus of ($2.72). EndoChoice sees FY2015 revenue of $73-76 million, versus the consensus of $73.6 million.

For earnings history and earnings-related data on EndoChoice (GI) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• Reaction roundup: Experts, analysts weigh in on September jobs report
• Investing.com’s stocks of the week